Last reviewed · How we verify
Tritanrix-HepB/Hib™ vaccine
Tritanrix-HepB/Hib™ vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, Prevention of invasive Hib disease.
Tritanrix-HepB/Hib™ vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.
Tritanrix-HepB/Hib™ vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, Prevention of invasive Hib disease.
At a glance
| Generic name | Tritanrix-HepB/Hib™ vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains inactivated or attenuated forms of the respective pathogens, which are administered to the patient to induce an immune response. The immune system recognizes these pathogens as foreign and mounts a response, producing antibodies that can neutralize or remove the pathogens from the body.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b
- Prevention of invasive Hib disease
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants (PHASE2)
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine (PHASE3)
- Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age. (PHASE3)
- Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (PHASE2)
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix-HepB/Hib™ vaccine CI brief — competitive landscape report
- Tritanrix-HepB/Hib™ vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Tritanrix-HepB/Hib™ vaccine
What is Tritanrix-HepB/Hib™ vaccine?
How does Tritanrix-HepB/Hib™ vaccine work?
What is Tritanrix-HepB/Hib™ vaccine used for?
Who makes Tritanrix-HepB/Hib™ vaccine?
What drug class is Tritanrix-HepB/Hib™ vaccine in?
What development phase is Tritanrix-HepB/Hib™ vaccine in?
What are the side effects of Tritanrix-HepB/Hib™ vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b
- Indication: Drugs for Prevention of invasive Hib disease
- Compare: Tritanrix-HepB/Hib™ vaccine vs similar drugs
- Pricing: Tritanrix-HepB/Hib™ vaccine cost, discount & access